Samsung Biologics' Unit Publishes PolyPeptide Group Tender Offer Prospectus

MT Newswires Live

Yesterday

Samsung Biologics (KRX:207940) said its Switzerland-based unit, Samsung Peptide, has published the prospectus for its public tender offer for PolyPeptide Group, according to a Monday release.

The offer includes 44.31 Swiss francs in cash per PolyPeptide share, implying an equity value of about 1.46 billion francs, and represents a 40% premium to the unaffected share price.

The offer is expected to run between Sept. 15 and Oct. 12, subject to a minimum acceptance threshold, and the largest individual shareholder, Draupnir Holding, with about a 55.65% stake, has committed to tendering all its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/2663605022"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2663605022\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2663605022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 13:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663605022","market":"hk","top_or_hot":-1,"title":"Samsung Biologics' Unit Publishes PolyPeptide Group Tender Offer Prospectus","media":"MT Newswires Live","content":"<html><body><p> Samsung Biologics (KRX:207940) said its Switzerland-based unit, Samsung Peptide, has published the prospectus for its public tender offer for PolyPeptide Group, according to a Monday release.</p><p>The offer includes 44.31 Swiss francs in cash per PolyPeptide share, implying an equity value of about 1.46 billion francs, and represents a 40% premium to the unaffected share price.</p><p>The offer is expected to run between Sept. 15 and Oct. 12, subject to a minimum acceptance threshold, and the largest individual shareholder, Draupnir Holding, with about a 55.65% stake, has committed to tendering all its shares.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsung Biologics' Unit Publishes PolyPeptide Group Tender Offer Prospectus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsung Biologics' Unit Publishes PolyPeptide Group Tender Offer Prospectus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-31 13:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Samsung Biologics (KRX:207940) said its Switzerland-based unit, Samsung Peptide, has published the prospectus for its public tender offer for PolyPeptide Group, according to a Monday release.</p><p>The offer includes 44.31 Swiss francs in cash per PolyPeptide share, implying an equity value of about 1.46 billion francs, and represents a 40% premium to the unaffected share price.</p><p>The offer is expected to run between Sept. 15 and Oct. 12, subject to a minimum acceptance threshold, and the largest individual shareholder, Draupnir Holding, with about a 55.65% stake, has committed to tendering all its shares.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2663605022","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2663605022","pubTimestamp":1788155112,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Samsung Biologics  said its Switzerland-based unit, Samsung Peptide, has published the prospectus for its public tender offer for PolyPeptide Group, according to a Monday release.The offer includes 44.31 Swiss francs in cash per PolyPeptide share, implying an equity value of about 1.46 billion francs, and represents a 40% premium to the unaffected share price.The offer is expected to run between Sept. 15 and Oct. 12, subject to a minimum acceptance threshold, and the largest individual shareholder, Draupnir Holding, with about a 55.65% stake, has committed to tendering all its shares.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4504":"桥水持仓","IEMG":"iShares Core MSCI Emerging Markets ETF","BK4588":"碎股","BK4550":"红杉资本持仓","EMXC":"iShares MSCI Emerging Markets ex China ETF","BK4585":"ETF&股票定投概念"},"translate_title":"三星生物制品部门发布多肽集团要约收购招股说明书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMXC":1.5,"IEMG":1.5},"content_text":"Samsung Biologics (KRX:207940) said its Switzerland-based unit, Samsung Peptide, has published the prospectus for its public tender offer for PolyPeptide Group, according to a Monday release.The offer includes 44.31 Swiss francs in cash per PolyPeptide share, implying an equity value of about 1.46 billion francs, and represents a 40% premium to the unaffected share price.The offer is expected to run between Sept. 15 and Oct. 12, subject to a minimum acceptance threshold, and the largest individual shareholder, Draupnir Holding, with about a 55.65% stake, has committed to tendering all its shares.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}